Objectives: Low-value esophagogastroduodenoscopies (EGDs) for uncomplicated gastro-oesophageal reflux disease (GERD) can harm patients and raise patient and payer costs. We developed an electronic health record (EHR) 'eMeasure' to detect low-value EGDs.
Design: Retrospective cohort of 518 adult patients diagnosed with GERD who underwent initial EGD between 1 January 2019 and 31 December 2019.
Setting: Outpatient primary care and gastroenterology clinics at a large, urban, academic health centre.
Participants: Adult primary care patients at the University of California Los Angeles who underwent initial EGD for GERD in 2019.
Main Outcome Measures: EGD appropriateness criteria were based on the American College of Gastroenterology 2012 guidelines. An initial EGD was considered low-value if it lacked a documented guideline-based indication, including alarm symptoms (eg, iron-deficiency anaemia); failure of an 8-week proton pump inhibitor trial or elevated Barrett's oesophagus risk. We performed manual chart review on a random sample of 204 patients as a gold standard of the eMeasure's validity. We estimated EGD costs using Medicare physician and facility fee rates.
Results: Among 518 initial EGDs performed (mean age 53 years; 54% female), the eMeasure identified 81 (16%) as low-value. The eMeasure's sensitivity was 42% (95% CI 22 to 61) and specificity was 93% (95% CI 89 to 96). Stratifying across clinics, 62 (74.6%) low-value EGDs originated from 2 (12.5%) out of 16 clinics. Total cost for 81 low-value EGDs was approximately US$75 573, including US$14 985 in patients' out-of-pocket costs.
Conclusions: We developed a highly specific eMeasure that showed that low-value EGDs occurred frequently in our healthcare system and were concentrated in a minority of clinics. These results can inform future QI efforts at our institution, such as best practice alerts for the ordering physician. Moreover, this open-source eMeasure has a much broader potential impact, as it can be integrated into any EHR and improve medical decision-making at the point of care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/bmjoq-2023-002363 | DOI Listing |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10749030 | PMC |
Cureus
October 2024
Gastroenterology, Hackensack Meridian Health, Palisades Medical Center, North Bergen, USA.
Cureus
October 2024
Dermatology, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, USA.
Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organ systems that often mimic other conditions. The majority of patients with SLE show mucocutaneous manifestations, fatigue, fever, rheumatological manifestations, and weight loss as initial symptoms. SLE is classically managed medically with hydroxychloroquine, glucocorticoids, and/or immunosuppressives.
View Article and Find Full Text PDFGastrointest Endosc
October 2024
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Cureus
September 2024
Department of Internal Medicine II, Fundeni Clinical Institute, Bucharest, ROU.
Gastric antral vascular ectasia (GAVE), commonly known as "watermelon stomach," is characterized by parallel red stripes resembling watermelon stripes on endoscopic examination and is an uncommon but significant cause of chronic gastrointestinal bleeding, often associated with systemic diseases such as autoimmune conditions, liver cirrhosis, chronic renal insufficiency, and cardiovascular disease. Various therapeutic approaches have been introduced for GAVE treatment, including medical, endoscopic, and surgical interventions. We report a case of a 60-year-old man with a prior history of GAVE who developed melena and symptomatic severe anemia.
View Article and Find Full Text PDFGastrointest Endosc
October 2024
Division of Gastroenterology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Columbus, Ohio, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!